Skip to content

The therapeutic effect of Tecar on patients with plantar fasciitis

Investigating the effect of Tacar treatment on improving symptoms and performance of patients with plantar fasciitis and comparing it with drug treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231105059968N1
Enrollment
60
Registered
2024-01-22
Start date
2025-02-19
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar fasciitis. Plantar fascial fibromatosis

Interventions

Intervention 1: Intervention group: Tecarotherapy (8 sessions: 2 days a week) and exercise (including stretching of calf muscles, plantar fascia, passive dorsiflexion of fingers, strengthening of intr

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 68 Years

Inclusion criteria

Inclusion criteria: Diagnosis of plantar fasciitis (worsening of the pain in the inner part of the heel in the morning after waking up and also after a lot of activity during the day and the presence of local tenderness in the lower inner part of the calcaneus) by a physical medicine and rehabilitation specialist with a physical examination Heel pain for at least 4 weeks Age between 18 and 68 years Presence of VAS greater than 3 Informed written consent to participate in the study

Exclusion criteria

Exclusion criteria: History of inflammatory joint disease Achilles tendon or nerve damage History of heel surgery or injection in the last 6 months History of injury to the affected heel The presence of diseases mimicking the symptoms of plantar fasciitis Contraindications of the Tecar device (pregnancy, pacemaker, insulin pump, growth plate, cancer, open wound and skin lesions, skin sensitivity, insensitivity to heat) Patients with intense physical activity or sports who are unable to reduce their activity level

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: The severity of symptoms and performance of patients before the treatment will be measured again immediately after the end of the treatment and 2 months after the end of the treatment. Method of measurement: Pain level of patients by Visual Analogue Scale questionnaire - intensity of symptoms and performance of patients by RM(The modified Roles and Maudsley) questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazieh Maghroori

Esfahan University of Medical Sciences

ramaghroori@yahoo.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026